- Home
- GFF vs XENE Comparison
GFF vs XENE Comparison
Compare GFF & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFF
- XENE
- Stock Information
- Founded
- GFF 1959
- XENE 1996
- Country
- GFF United States
- XENE Canada
- Employees
- GFF N/A
- XENE N/A
- Industry
- GFF Building Products
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- GFF Industrials
- XENE Health Care
- Exchange
- GFF Nasdaq
- XENE Nasdaq
- Market Cap
- GFF 3.8B
- XENE 3.3B
- IPO Year
- GFF N/A
- XENE 2014
- Fundamental
- Price
- GFF $72.76
- XENE $38.63
- Analyst Decision
- GFF Strong Buy
- XENE Strong Buy
- Analyst Count
- GFF 4
- XENE 9
- Target Price
- GFF $89.25
- XENE $56.67
- AVG Volume (30 Days)
- GFF 393.2K
- XENE 418.4K
- Earning Date
- GFF 02-05-2025
- XENE 11-12-2024
- Dividend Yield
- GFF 0.99%
- XENE N/A
- EPS Growth
- GFF 197.89
- XENE N/A
- EPS
- GFF 4.23
- XENE N/A
- Revenue
- GFF $2,623,520,000.00
- XENE N/A
- Revenue This Year
- GFF $0.93
- XENE N/A
- Revenue Next Year
- GFF $3.10
- XENE $1,599.99
- P/E Ratio
- GFF $17.22
- XENE N/A
- Revenue Growth
- GFF N/A
- XENE N/A
- 52 Week Low
- GFF $55.01
- XENE $35.53
- 52 Week High
- GFF $86.73
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- GFF 38.14
- XENE 39.23
- Support Level
- GFF $71.01
- XENE $37.52
- Resistance Level
- GFF $82.32
- XENE $41.62
- Average True Range (ATR)
- GFF 2.21
- XENE 1.66
- MACD
- GFF -1.56
- XENE -0.34
- Stochastic Oscillator
- GFF 14.47
- XENE 18.94
About GFF Griffon Corporation
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products and Home and Building Products. The company generates a majority of its revenue from the Home and Building Products segment.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.